13hon MSN
From lab to clinic: Phase I trial of promising combination therapy for resistant ovarian cancer
Researchers at the University of Colorado Cancer Center have discovered a novel therapy combination that could offer new hope ...
Researchers say this is the first combination therapy that targets two different cancer survival mechanism: PARP and WNT signaling.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback